Why We’re Publishing This Now

This analysis is not an attempt to “call” a shortage into existence. The events described here have already occurred. This is a post-event analysis.

By the time of publication:

• international shortage notifications had already been reported for many months

• pharmacy acquisition prices had already increased sharply

• branded and special-order products had already re-entered routine supply

• and the Department of Health and Social Care had already issued a £2.70 price concession

These are not early warnings or speculative indicators. They are formal developments that had already taken place, collectively indicating that the Rosuvastatin market was operating under sustained stress before it was formally recognised as such.

**Rosuvastatin in the NHS **

Rosuvastatin is a cornerstone medicine in modern cardiovascular care and is prescribed at scale across both primary and secondary settings.

In NHS England, primary care prescribing volumes have more than doubled since 2021, with secondary care use also increasing steadily over the same period.

Following patent expiry, the UK market expanded rapidly. Multiple suppliers entered, and reimbursement for Rosuvastatin 10 mg tablets fell from approximately £19 per pack to below £1, delivering substantial savings for the NHS.

Over time, however, continued price reductions combined with rising volumes altered the market’s structure. Supplier participation reduced, not suddenly, but progressively, leaving behind a narrower market with less depth and less tolerance for disruption.

Global Supply Failure

By mid-2025, Rosuvastatin was already showing signs of supply failure across multiple international markets.

Shortage notifications, supply alerts, out-of-stock notices, and discontinuations were being reported with increasing frequency. These reports were not confined to a single geography or manufacturer and were increasingly concentrated around commonly prescribed tablet strengths.

At the same time, manufacturing delays and quality-related batch withdrawals began to appear, further tightening supply in a market with limited redundancy.

Taken together, these signals described a pattern rather than a series of isolated events. Across markets, Rosuvastatin supply was becoming less reliable under similar economic and operational pressures.

While Global Supply Signals Emerged, UK Prices Continued to Decline

Over the same period, UK Drug Tariff reimbursement continued to move downwards.

From early 2025 through early 2026, reimbursement for Rosuvastatin 10 mg tablets reduced in a series of incremental steps:

• from approximately £0.91

• to £0.88

• then £0.83

• then £0.79

• and finally £0.76

Two signals were moving in opposite directions:

• globally, supply systems were increasingly reporting disruption

• domestically, pricing decisions continued to reflect confidence in ongoing resilience

The pricing signal implied that further reductions remained possible, even as international supply conditions deteriorated.

The UK Front Line Saw It First

In the UK, community pharmacy experienced the effects of this imbalance well before any formal policy response.

For Rosuvastatin 10 mg (28 tablets), acquisition prices increased rapidly over a short period, rising from approximately £0.30 to over £2.20 per pack.

In February 2026, a £2.70 price concession was granted. By that point, market conditions had already shifted materially, and higher-cost products had begun to re-establish themselves in routine supply.

Current Market Position

Today, supply disruption is visible across community pharmacy, wholesaling, and manufacturing.

Availability remains inconsistent across multiple strengths and brands, with pressure concentrated at the lower end of the price spectrum:

• low-priced generics (£0.80–£1.50) are overwhelmingly out of stock

• multiple core generics are reported as “out of stock” or “limited availability”

• branded Crestor and parallel imports are available at approximately £18–£29 per pack

• alternatives, including specials, liquids, and sprinkles, are filling gaps at prices ranging from £9 to £190

Despite these conditions, Rosuvastatin is not currently classified as an official UK shortage.

Existing shortage frameworks are designed to identify physical absence. They do not capture economic non-viability or the gradual erosion of supply resilience.

As a result, Rosuvastatin occupies a grey zone: not absent, not stable, and not formally recognised as short. It is within this space that supply risk is most easily overlooked and allowed to persist.

Visibility Gaps in the System

Recent parliamentary analysis has highlighted structural limitations in how medicines supply risk is monitored in the UK.

Despite multiple reporting mechanisms and stakeholder engagement processes, visibility across the entire suppy remains incomplete. This limits the system’s ability to identify emerging risks early, assess market depth accurately, and respond proportionately.

In practice, this means that rising acquisition prices, supplier withdrawals, and narrowing availability can remain visible at the market level without triggering timely policy recognition.

Rosuvastatin’s current position reflects this limitation. Supply has not ceased, but the conditions that once supported stability have materially weakened.

A Final Reflection

The developments described above did not occur suddenly. They accumulated over time and were observable through international shortage notifications, recalls, domestic pricing behaviour, supplier participation, and the re-emergence of higher-cost alternatives.

These signals were visible before Rosuvastatin was treated as a problem.

Rosuvastatin has not experienced a complete supply failure. However, the market supporting it has narrowed, thinned, and become increasingly reliant on products that sit outside its original low-cost structure.

This is not an isolated example, many other shortages show the same pattern and also unrecognised until it is too late.recognised too late.